estalis sequi
novartis new zealand ltd - estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours; ; estradiol hemihydrate 0.62mg equivalent to 50 µg/24 hours; norethisterone acetate 2.7mg equivalent to 140 µg/24 hours; - transdermal patch - 50/140 - active: estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive active: estradiol hemihydrate 0.62mg equivalent to 50 µg/24 hours norethisterone acetate 2.7mg equivalent to 140 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive
estalis sequi
novartis new zealand ltd - estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours; ; estradiol hemihydrate 0.512mg equivalent to 50 µg/24 hours; norethisterone acetate 4.8mg equivalent to 250 µg/24 hours; - transdermal patch - 50/250 - active: estradiol hemihydrate 0.78mg equivalent to 50 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive active: estradiol hemihydrate 0.512mg equivalent to 50 µg/24 hours norethisterone acetate 4.8mg equivalent to 250 µg/24 hours excipient: acrylic adhesive dipropylene glycol oleic acid povidone silicone adhesive
kliovance
novo nordisk pharmaceuticals ltd - estradiol hemihydrate 1.03mg equivalent to 1 mg oestradiol; ; ; ; norethisterone acetate 0.5mg; ; ; - film coated tablet - active: estradiol hemihydrate 1.03mg equivalent to 1 mg oestradiol norethisterone acetate 0.5mg excipient: copovidone hypromellose lactose monohydrate magnesium stearate maize starch purified talc triacetin
kliovance low
novo nordisk pharmaceuticals ltd - estradiol hemihydrate 0.517mg; ; ; norethisterone acetate 0.1mg; ; - film coated tablet - active: estradiol hemihydrate 0.517mg norethisterone acetate 0.1mg excipient: hyprolose hypromellose lactose monohydrate magnesium stearate maize starch purified talc triacetin - kliovance low is indicated for the treatment of menopausal symptoms related to oestrogen deficiency. kliovance low is also indicated for the prevention of osteoporosis in postmenopausal women. the experience of treating women older than 65 years is limited.
activelle
novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone as acetate - film coated tablets - estradiol as hemihydrate 1 mg; norethisterone as acetate 0.5 mg - norethisterone and estrogen - norethisterone and estrogen - hormone replacement therapy (hrt) for oestrogen deficiency symptoms in women more than one year after menopause. prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of , or contraindicated for, other medicinal products approved for the prevention of osteoporosis. the experience treating women older than 65 years is limited.
estalis 50/250 50/250 microgram/day transdermal patch
novartis pharmaceuticals uk ltd - estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day
estalis sequi 50/250 microgram/day transdermal patch
novartis pharmaceuticals uk ltd - estradiol hemihydrate estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day
sequidot 50/250 microgram/day transdermal patch
novartis pharmaceuticals uk ltd - estradiol hemihydrate estradiol hemihydrate norethisterone acetate - transdermal patch - 50/250 microgram/day
activelle tablet
novo nordisk pharma (singapore) pte ltd - estradiol (as hemihydrate) micronized; norethisterone acetate micronized - tablet, film coated - 1 mg - estradiol (as hemihydrate) micronized 1 mg; norethisterone acetate micronized 0.5 mg
estrofem estradiol (as hemihydrate) 2mg tablet dial dispenser pack
novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.